Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
Although a product may be reasonably safe when it is sold, a manufacturer that later learns of risks revealed by user operation may be held responsible for failure to issue post-sale warnings. The justification for a post-sale duty to warn arises from a manufacturer's unique and superior position to follow the use and adaptation of its products by consumers. The manufacturer is best placed to learn about post-sale defects or dangers discovered in the use of its products as compared with purchasers and users.
Although a manufacturer is generally not responsible for injuries caused by substantial alterations by a third party that renders the product unsafe, even where a substantial modification has been made, an injured plaintiff may claim a post-sale failure to warn. See Liriano v. Hobart, 92 NY2d 232, 677 NYS2d 764 (1998), 170 F3d 264 (2d Cir. 1999).
If the plaintiff's lawyer cannot find any evidence that the manufacturer knew of post-sale dangers or modifications, the plaintiff has not met its burden. The first place a practitioner should look to find prior complaints is the Web site of whichever governmental organization regulates the product. The site will generally point in the direction of a helpful source. For example, National Highway Traffic Safety Administration (NHTSA) has a fine library available to the public for automotive research. Even though a recall may not have been necessitated, NHTSA is still the place to find reports by displeased car owners. For drugs, the Food and Drug Administration (FDA) will have information on products taken off the market, as well as reports of adverse drug reactions, even if the product is still on the market.
Once a practitioner has consulted all government organizations, he or she should make inquires of industry organizations to learn of the existence of industry-wide investigations. Private organizations, such as the Insurance Institute for Highway Safety (IIHS), are another place to find post-sale problems of which auto manufacturers are, or should be, aware.
Of course, the best place to look for post-sale notice of defects is with the defendant. A factory sales or service representative who has visited the factory where the product is being used and who may have seen and reported misuse or modifications to his or her employer/manufacturer usually is a good witness to depose. In drug cases, a lawyer is more likely to learn about adverse reactions from “detail men” than from a manufacturer's letters from physicians. (It is well known that doctors rarely write to drug manufacturers about adverse reactions.)
All of these are possible sources to prove notice to manufacturers in order to recover under the theory of post-sale warnings.
Although a product may be reasonably safe when it is sold, a manufacturer that later learns of risks revealed by user operation may be held responsible for failure to issue post-sale warnings. The justification for a post-sale duty to warn arises from a manufacturer's unique and superior position to follow the use and adaptation of its products by consumers. The manufacturer is best placed to learn about post-sale defects or dangers discovered in the use of its products as compared with purchasers and users.
Although a manufacturer is generally not responsible for injuries caused by substantial alterations by a third party that renders the product unsafe, even where a substantial modification has been made, an injured plaintiff may claim a post-sale failure to warn. See
If the plaintiff's lawyer cannot find any evidence that the manufacturer knew of post-sale dangers or modifications, the plaintiff has not met its burden. The first place a practitioner should look to find prior complaints is the Web site of whichever governmental organization regulates the product. The site will generally point in the direction of a helpful source. For example, National Highway Traffic Safety Administration (NHTSA) has a fine library available to the public for automotive research. Even though a recall may not have been necessitated, NHTSA is still the place to find reports by displeased car owners. For drugs, the Food and Drug Administration (FDA) will have information on products taken off the market, as well as reports of adverse drug reactions, even if the product is still on the market.
Once a practitioner has consulted all government organizations, he or she should make inquires of industry organizations to learn of the existence of industry-wide investigations. Private organizations, such as the Insurance Institute for Highway Safety (IIHS), are another place to find post-sale problems of which auto manufacturers are, or should be, aware.
Of course, the best place to look for post-sale notice of defects is with the defendant. A factory sales or service representative who has visited the factory where the product is being used and who may have seen and reported misuse or modifications to his or her employer/manufacturer usually is a good witness to depose. In drug cases, a lawyer is more likely to learn about adverse reactions from “detail men” than from a manufacturer's letters from physicians. (It is well known that doctors rarely write to drug manufacturers about adverse reactions.)
All of these are possible sources to prove notice to manufacturers in order to recover under the theory of post-sale warnings.
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN ENTERTAINMENT LAW.
Already a have an account? Sign In Now Log In Now
For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473
With each successive large-scale cyber attack, it is slowly becoming clear that ransomware attacks are targeting the critical infrastructure of the most powerful country on the planet. Understanding the strategy, and tactics of our opponents, as well as the strategy and the tactics we implement as a response are vital to victory.
This article highlights how copyright law in the United Kingdom differs from U.S. copyright law, and points out differences that may be crucial to entertainment and media businesses familiar with U.S law that are interested in operating in the United Kingdom or under UK law. The article also briefly addresses contrasts in UK and U.S. trademark law.
The Article 8 opt-in election adds an additional layer of complexity to the already labyrinthine rules governing perfection of security interests under the UCC. A lender that is unaware of the nuances created by the opt in (may find its security interest vulnerable to being primed by another party that has taken steps to perfect in a superior manner under the circumstances.
Ideally, the objective of defining the role and responsibilities of Practice Group Leaders should be to establish just enough structure and accountability within their respective practice group to maximize the economic potential of the firm, while institutionalizing the principles of leadership and teamwork.
In Rockwell v. Despart, the New York Supreme Court, Third Department, recently revisited a recurring question: When may a landowner seek judicial removal of a covenant restricting use of her land?